Kimia Farma (Indonesia) Performance
| KAEF Stock | IDR 605.00 5.00 0.82% |
The company secures a Beta (Market Risk) of 0.2, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kimia Farma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kimia Farma is expected to be smaller as well. At this point, Kimia Farma Persero has a negative expected return of -0.31%. Please make sure to verify Kimia Farma's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Kimia Farma Persero performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kimia Farma Persero has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward-looking signals remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 1.2 T | |
| Total Cashflows From Investing Activities | -648.5 B |
Kimia |
Kimia Farma Relative Risk vs. Return Landscape
If you would invest 74,500 in Kimia Farma Persero on September 1, 2024 and sell it today you would lose (14,000) from holding Kimia Farma Persero or give up 18.79% of portfolio value over 90 days. Kimia Farma Persero is generating negative expected returns and assumes 1.9622% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Kimia, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Kimia Farma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kimia Farma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kimia Farma Persero, and traders can use it to determine the average amount a Kimia Farma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1559
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KAEF |
Estimated Market Risk
| 1.96 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kimia Farma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kimia Farma by adding Kimia Farma to a well-diversified portfolio.
Kimia Farma Fundamentals Growth
Kimia Stock prices reflect investors' perceptions of the future prospects and financial health of Kimia Farma, and Kimia Farma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kimia Stock performance.
| Return On Equity | -0.026 | |||
| Return On Asset | 0.0089 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 14.62 T | |||
| Shares Outstanding | 5.55 B | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 0.60 X | |||
| Revenue | 12.86 T | |||
| EBITDA | 1.23 T | |||
| Cash And Equivalents | (1.54 B) | |||
| Cash Per Share | 122.65 X | |||
| Total Debt | 3.25 T | |||
| Debt To Equity | 1.09 % | |||
| Book Value Per Share | 1,298 X | |||
| Cash Flow From Operations | (223.92 B) | |||
| Earnings Per Share | 7.09 X | |||
| Total Asset | 17.76 T | |||
About Kimia Farma Performance
By examining Kimia Farma's fundamental ratios, stakeholders can obtain critical insights into Kimia Farma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Kimia Farma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
PT Kimia Farma Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, rest of Asia, Europe, Australia, Africa, and New Zealand. The company was founded in 1817 and is headquartered in Jakarta, Indonesia. Kimia Farma operates under Drug ManufacturersSpecialty Generic classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 11772 people.Things to note about Kimia Farma Persero performance evaluation
Checking the ongoing alerts about Kimia Farma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kimia Farma Persero help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kimia Farma Persero generated a negative expected return over the last 90 days | |
| Kimia Farma Persero has accumulated about (1.54 B) in cash recording (223.92 B) of negative cash flow from operations. This results in cash-per-share (CPS) ratio of 122.65. | |
| Roughly 96.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Kimia Farma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kimia Farma's stock is overvalued or undervalued compared to its peers.
- Examining Kimia Farma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kimia Farma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kimia Farma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kimia Farma's stock. These opinions can provide insight into Kimia Farma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Kimia Stock
Kimia Farma financial ratios help investors to determine whether Kimia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kimia with respect to the benefits of owning Kimia Farma security.